Please use this identifier to cite or link to this item:
http://hdl.handle.net/10603/589839
Title: | Impact of Formulation and Process Variables on the Development of Extended Release Matrix Tablets |
Researcher: | Arunkumar Alias Arumugarajan M |
Guide(s): | Geetha G |
Keywords: | Cilostazol Etodoalc ER tablets Extended Release Matrix Tablets Formulation Impact Process Variables |
University: | The Tamil Nadu Dr. M.G.R. Medical University |
Completed Date: | 2014 |
Abstract: | The main objective of the current research was to design, optimize and evaluate of sustained release Etodolac extended release tablets and cilostazol sustained release tablets and to study the different formulation and process variables. INTRODUCTION: In market, 50 mg and 100 mg Immediate Release tablet is available. Daily dose of cilostazol is 200 mg/day. It is observed more side effects due to conventional dose. The sustained release cilostazol tablet has a long release time so that the sustains release cilostazol tablet can be taken once daily for convenience of drug use and minimizes the manifestation of headache which is one side effect caused when women take conventional cilostazol preparations, so that the convenience of drug use can be improved. The slow-release cilostazol tablet exhibits a stable elution pattern with no variation in release rate according to changes in pH in the stomach and intestines, as well as an effect of delaying the release of a drug, by release-controlling polymer. PLAN OF WORK: It describes the aim and objective of the research work and mentions in brief, the plan of work that was undertaken. PREFORMULATION STUDIES: Standardization of the drug was carried out for cilostazol tablet, a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating agent with respect to its organoleptic parameters, bulk characterization, solubility and stability analysis and other parameters like melting point and moisture content and has been reported in this chapter along with the literature review for the respective drugs. CONCLUSION: we report that etodolac, non-steroidal anti-inflammatory were developed with different manufacturing methods and polymers as an extended release tablets. Etodoalc ER tablets formulated with xanthan gum by wet granulation found to be enhanced than kollidon SR formulation. Cilostazol, selective inhibitor of phosphodiesterase-II were developed with different manufacturing methods and polymers as a sustained release tablets. |
Pagination: | 204 |
URI: | http://hdl.handle.net/10603/589839 |
Appears in Departments: | Department of Pharmacy |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
01_title.pdf | Attached File | 515.85 kB | Adobe PDF | View/Open |
02_prelim pages.pdf | 9.82 MB | Adobe PDF | View/Open | |
03_content.pdf | 751.82 kB | Adobe PDF | View/Open | |
05_chapter 1.pdf | 5.94 MB | Adobe PDF | View/Open | |
06_chapter 2.pdf | 1.48 MB | Adobe PDF | View/Open | |
07_chapter 3.pdf | 4.67 MB | Adobe PDF | View/Open | |
08_chapter 4.pdf | 20.87 MB | Adobe PDF | View/Open | |
09_chapter 5.pdf | 29.09 MB | Adobe PDF | View/Open | |
10_annexures.pdf | 5.02 MB | Adobe PDF | View/Open | |
10_chapter 6.pdf | 11.45 MB | Adobe PDF | View/Open | |
11_chapter 7.pdf | 3.67 MB | Adobe PDF | View/Open | |
80_recommendation.pdf | 3.15 MB | Adobe PDF | View/Open |
Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
Altmetric Badge: